$8.26 Billion is the total value of Redmile Group, LLC's 87 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| STTK | New | SHATTUCK LABS INC | $294,540,000 | – | 5,619,914 | +100.0% | 3.57% | – |
| MDVL | New | MEDAVAIL HOLDINGS INC | $176,457,000 | – | 11,724,726 | +100.0% | 2.14% | – |
| ABBV | New | ABBVIE INC | $148,821,000 | – | 1,388,904 | +100.0% | 1.80% | – |
| GWPH | New | GW PHARMACEUTICALS PLCads | $94,138,000 | – | 815,681 | +100.0% | 1.14% | – |
| AVIR | New | ATEA PHARMACEUTICALS INC | $93,241,000 | – | 2,231,710 | +100.0% | 1.13% | – |
| UNH | New | UNITEDHEALTH GROUP INC | $78,776,000 | – | 224,639 | +100.0% | 0.95% | – |
| ANTM | New | ANTHEM INC | $78,453,000 | – | 244,332 | +100.0% | 0.95% | – |
| UBER | New | UBER TECHNOLOGIES INC | $42,526,000 | – | 833,845 | +100.0% | 0.52% | – |
| CNC | New | CENTENE CORP DEL | $33,314,000 | – | 554,962 | +100.0% | 0.40% | – |
| ABCL | New | ABCELLERA BIOLOGICS INC | $20,120,000 | – | 500,000 | +100.0% | 0.24% | – |
| LUNG | New | PULMONX CORP | $18,981,000 | – | 275,000 | +100.0% | 0.23% | – |
| VSPR | New | VESPER HEALTHCARE ACQSTN COR | $11,310,000 | – | 1,000,000 | +100.0% | 0.14% | – |
| YMTX | New | YUMANITY THERAPEUTICS INC | $10,387,000 | – | 611,003 | +100.0% | 0.13% | – |
| SEER | New | SEER INC | $7,018,000 | – | 125,000 | +100.0% | 0.08% | – |
| EAR | New | EARGO INC | $5,804,000 | – | 129,488 | +100.0% | 0.07% | – |
| MASS | New | 908 DEVICES INC | $4,271,000 | – | 75,000 | +100.0% | 0.05% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 43 | Q3 2023 | 10.1% |
| ATARA BIOTHERAPEUTICS INC | 36 | Q3 2023 | 6.4% |
| FATE THERAPEUTICS INC | 34 | Q3 2023 | 17.2% |
| INVITAE CORP | 32 | Q3 2023 | 2.7% |
| REGENXBIO INC | 28 | Q3 2023 | 3.8% |
| CLOVIS ONCOLOGY INC | 27 | Q1 2020 | 6.7% |
| IMMUNOGEN INC | 27 | Q3 2023 | 13.2% |
| CASTLIGHT HEALTH INC SAN FRAN COM STK | 27 | Q1 2021 | 2.5% |
| ARRAY BIOPHARMA INC | 26 | Q2 2019 | 12.6% |
| DECIPHERA PHARMACEUTICALS IN | 25 | Q3 2023 | 7.0% |
View Redmile Group, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | July 27, 2023 | 2,912,228 | 6.6% |
| IGM Biosciences, Inc. | June 28, 2023 | 3,291,092 | 9.9% |
| MedAvail Holdings, Inc. | June 21, 2023 | 124,507,268 | 73.1% |
| Achilles Therapeutics plc | February 14, 2023 | 1,608,089 | 3.9% |
| Kymera Therapeutics, Inc. | February 14, 2023 | 2,673,837 | 4.9% |
| Old Ayala, IncSold out | February 08, 2023 | 0 | 0.0% |
| Zymeworks Inc. | August 08, 2022 | 5,758,241 | 9.9% |
| Science 37 Holdings, Inc. | June 15, 2022 | 19,808,234 | 17.1% |
| Allakos Inc. | February 14, 2022 | 2,077,875 | 3.8% |
| Aprea Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Redmile Group, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-19 |
| 4 | 2024-03-14 |
| 4 | 2024-03-13 |
| SC 13D/A | 2024-03-13 |
| 4 | 2024-03-05 |
| SC 13D/A | 2024-03-05 |
View Redmile Group, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.